Infantile Hemangioma: A Retrospective Study

Lydiawati, Eva; Zulkarnain, Iskandar

doi:10.20473/bikk.v32.1.2020.21-26

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This value is consistent with the findings of Lydiawati and Zulkarnain, who found that IHs are common in children under the age of 1 year. This condition develops actively during the first few weeks after birth and lasts until it spontaneously involutes around 1 year of age (16).…”

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Propranolol in Treating Infantile Hemangioma: A Prospective Study

Khalilian,

Esmaeili,

Vahidi

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

: Hemangiomas are benign vascular tumors that often develop in infants. The most common treatment option for complicated hemangiomas is propranolol. We discuss the use of oral propranolol in treating infantile hemangioma (IH) in an Iranian population at our hospital. We conducted a cross-sectional prospective descriptive study on 62 infants aged 1 to 16 months from 2017 to 2021. Propranolol was gradually administered orally at a dose of 3 mg/kg/day. The hemangioma score was examined at 6 intervals (first visit, 1, 3, 6, 9, and 12 months later). Propranolol therapies were stopped when there was no further decrease in scores for 2 successive visits. The study was completed by 62 patients. In terms of hemangiomas, 46 (74.2%) patients had 1 lesion, 12 (19.4%) had 2 lesions, and 4 (6.5%) had 3 lesions. Over time, the average size of hemangiomas steadily decreased, such that 5 patients (9.1%) were completely treated; 1 patient improved after 3 months, 3 after 6 months, 1 after 9 months, and 57 (91.9%) were partially treated. Aside from being safe and effective, propanol can also obtain a higher response rate when treatment is started early in infants aged less than 3 months.

show abstract

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Propranolol in Treating Infantile Hemangioma: A Prospective Study

Khalilian,

Esmaeili,

Vahidi

et al. 2023

Iran J Pharm Res

View full text Add to dashboard Cite

show abstract

“…The most common IH location was the facial region in 49 patients (58.33%). 6 Continuous exploration and optimization of therapeutic regimens have been carried out in recent years for IH. many curative therapeutic regimens have emerged and been applied in clinical practice, including oral medications, injectable medications, topical medications, laser therapy, and surgical treatment.…”

Section: Introductionmentioning

confidence: 99%

Excellent Response of Infantile Hemangioma with Oral Propranolol: A Case Report

Denissafitri

Pramitha

Widia

et al. 2022

BIKK

View full text Add to dashboard Cite

Background: Infantile hemangioma (IH) is the most common benign tumor in infancy. Most IHs resolve spontaneously and do not require treatment. Therapeutic intervention is necessary for life-threatening IH, tumors posing functional risks, ulceration, and severe anatomic distortion, especially on the face. Beta-blockers, most specifically propranolol, have been shown to induce involution of IH, which should be administered as early as possible to avoid potential complications. Purpose: To report a case of IH with visual impairment treated successfully using oral propranolol. Case: A 4-month-old girl weighing, 6.3 kg, with redness plaques on the right face since 3 weeks after birth. The lesions rapidly increased in size within 2 months, and the lesions on her right eyelid made it difficult to open her right eye. Dermatological examination showed erythematous plaques, compressible and varying in size and ptosis. The patient was diagnosed with periocular infantile hemangioma and was given oral propranolol therapy with an initiated dose 3x1 mg. The dose was increased gradually. The lesions were significantly decreased and she could open her right eye normally after 5 months of propranolol therapy. Discussion: Some cases of IH require early treatment. Early treatment is indicated for IH causing functional impairment. The use of propranolol in the management of IH is very effective in the reduction of the lesions and Has minimal side effects. Conclusion: Early diagnosis and intervention with propranolol for IH play an important role in determining the optimal outcomes.

show abstract

The Profiles of Infantile Hemangiomas Patients

Hidayati

Earlia

Sari³

et al. 2023

BIKK

View full text Add to dashboard Cite

Background: Infantile hemangiomas (IH) are the most prevalent benign tumors in children, predominantly in girls. Most IH cases do not require treatment due to spontaneous involution, but 10% of cases do require early treatment due to size, location, and complications. Purpose: This study tried to define the profile, clinical aspects, and therapy of IH in Dr. Zainoel Abidin General Hospital, Banda Aceh. Methods: A descriptive approach using a retrospective analysis employing secondary data from the outpatient clinic's patient registration book. This study included all new cases of infantile hemangioma at the outpatient clinic general hospital between 2013 and 2021. Result: A total of 105 patients were involved in this study. The majority of IH patients (59%) were under the age of one year, with 64 female patients (61%) making the most visits to the pediatric clinic in 2017, 2018, and 2019 (77.1%). The most prevalent clinical features of skin lesions were nodules in 69 individuals (65.7%), and the most common site was the facial region (13.3%) in 44 patients. In 20 individuals, a combination of propanolol and oral corticosteroids was used as the most effective treatment strategy (19% ). Conclusion: Infantile hemangiomas is the most frequently reported benign tumor in children. Females are more likely than males to develop IH. The majority of IH is minor and normally resolves on its own without therapy. However, certain rare kinds of IH require clinician attention and systematic treatment.

show abstract

Infantile Hemangioma: A Retrospective Study

Cited by 3 publications

References 19 publications

The Efficacy and Safety of Propranolol in Treating Infantile Hemangioma: A Prospective Study

The Efficacy and Safety of Propranolol in Treating Infantile Hemangioma: A Prospective Study

Excellent Response of Infantile Hemangioma with Oral Propranolol: A Case Report

The Profiles of Infantile Hemangiomas Patients

Contact Info

Product

Resources

About